Purpose: Nonsmall cell lung cancer (NSCLC) patient radiation therapy (RT) is planned without consideration of spatial heterogeneity in lung function or tumor response. We assessed the dosimetric and clinical feasibility of functional lung avoidance and response-adaptive escalation (FLARE) RT to reduce dose to [
INTRODUCTION
The prognosis of patients with locally advanced and unresectable nonsmall cell lung cancer (NSCLC) is poor with a median survival of 29 months. 1 Even though concurrent chemoradiotherapy is the standard treatment option for these patients, long-term survival remains elusive in most of these patients and is impacted by a high rate of local failure. 2 Current treatment regimens achieve suboptimal tumor control with local failure up to 50% and 5-year overall survival of 10-20%, while carrying substantial risk of toxicity, with grade 3 or higher pulmonary toxicity seen in approximately 20% of patients. [3] [4] [5] [6] Potential improvement of local control rates by dose escalation above the standard 60 Gy in conventional fractionation was initially felt to be promising. 6, 7 However, uniform dose escalation to the entire tumor volume in unselected patients with locally advanced NSCLC failed to improve outcomes within the construct of a randomized trial (RTOG 0617), where overall survival was inferior in the 74 Gy arm compared to the 60 Gy arm. 1 This reveals the importance of identifying a safe dose escalation strategy. Giving more radiation dose uniformly across an entire patient population will likely cause as much toxicity as benefit and therefore it is essential to strategize on how to identify patients at high risk of local failure after conventional radiation doses of 60 Gy.
Patients with NSCLC exhibit heterogeneous responses to conventional radiotherapy treatment. Some patients are at high risk of local failure and require additional therapy to achieve tumor control, some are at high risk of serious side effects in need of strategies to minimize toxicity, and some are at high risk of both. Fluorodeoxyglucose positron emission tomography ([ 18 F]FDG PET) has been widely utilized for evaluating the response to therapy 8 and several studies have shown that the standardized FDG uptake value in the tumor was a significant prognostic factor in NSCLC. [9] [10] [11] Response assessment with FDG PET/CT can predict for poor local control and survival, 12 whereby one study looking at mid-treatment PET/CT showed that 60% of patients were classified as nonresponders with 2-year overall survival of 33% compared to 92% in responders. 13 FDG PET/CT can also identify gross tumor subregions that spatially correlate to recurrent disease. [14] [15] [16] PET-guided radiation therapy (RT) dose escalation trials are delineating FDG PET avid tumor regions prior to 17 and during (RTOG 1106) treatment for concomitant dose escalation in randomized locally advanced NSCLC cohorts. Effective RT for patients with locally advanced NSCLC likely requires selection of a subpopulation with significant survival benefit from dose intensification.
Improvements in the therapeutic ratio through tumor dose escalation are limited by increased risk of pulmonary toxicity, particularly in the form of radiation-induced pneumonitis or fibrosis. As high as 40% of patients develop clinically significant radiation pneumonitis after conventionally fractionated radiation treatment. 18 Lung tissue treated with radiation can also develop fibrosis as a long-term side effect resulting in functional loss due to impaired gas exchange. Current standard practice in radiation oncology is to limit the mean radiation dose to the lung and percent of lung volume receiving at least 20 Gy to minimize the risk of radiation pneumonitis. However, this approach does not differentiate between functional and nonfunctional lung.
Perfusion SPECT/CT imaging using 99m Tc-labeled macroaggregated albumin (MAA) is commonly performed as a noninvasive diagnostic imaging test of pulmonary function. It is utilized by surgeons to predict postoperative lung function 19 and has potential for use in RT planning as a tool for functional lung avoidance planning. Conventional RT planning based on anatomic lung dose constraints yielded large variability in dose to functional lung across patients, 20 which can be accounted for functional avoidance planning. Prior studies using planar scintigraphy and MAA SPECT perfusion scans with long-term follow-up provide rationale for modeling regional perfusion reduction as a function of delivered radiation dose. 21, 22 Independent investigations were able to link perfusion SPECT-weighted radiation dose to lung to incidence of post-RT pulmonary toxicity. 23, 24 Modern SPECT/CT imaging techniques could overcome technical limitations in spatial resolution and quantitative accuracy that limited prior studies from establishing firm links between regional perfusion deficits and pulmonary toxicity. 25 Besides perfusion, ventilation imaging approaches for functional lung avoidance planning have also shown conceptual promise to reduce pulmonary toxicity risk. Recent investigations have reported on the use of 68 Ga-galligas PET, 26 hyperpolarized 3 He MRI, 27 and 4DCT deformation fields to derive ventilation maps. [28] [29] [30] Their ability to distinguish between acute and chronic airway obstruction 28 can inform
Medical Physics, 44 (7), July 2017 on functional region definition and functional lung radiotherapy planning constraints. 30 While combined lung ventilation and perfusion promote efficient gas exchange necessary for function, it remains to be determined which physiologic process characterized by the above imaging techniques best predicts radiation-induced pulmonary toxicity, given the variable timescales at which airway constriction and vasoconstriction occur in response to radiation damage. 31 The avoidance of MAA SPECT-defined lung tissue regions at risk for morbidity and response-adaptive dose escalation to FDG PET-defined tumor tissue regions at risk for recurrence are motivated by clinical evidence. 15, 16, [32] [33] [34] In response to this evidence, a novel investigator-initiated clinical trial (NCT02773238) has been launched to test the efficacy of a precision radiation oncology strategy known as Functional Lung Avoidance and Response-adaptive Escalation Radiation Therapy (FLARE RT). The strategy accounts for spatial heterogeneity on FDG PET/CT and data-corrected MAA SPECT/CT imaging to dose-paint-by-numbers 35 at the voxel scale within both cancer and lung tissue regions simultaneously. As a precursor to the trial, the purpose of this study was to evaluate the clinical feasibility of FLARE RT beyond its conceptual feasibility, to characterize the achievable dosimetry of target and normal tissues under standardized constraints dictated by clinical protocol compliance, and to calculate the magnitude and linearity of functional imageguided dose redistribution in a sample of locally advanced NSCLC patients. This represents an evolutionary leap from a previous proof-of-concept investigation, 36 and provides the FLARE RT trial with a technical framework that can help address the questions raised by negative results of uniform dose escalation. 1,37,38
METHODS

2.A. Patient characteristics
Under an observational imaging study (NCT01982123) with approval by the Institutional Review Board, a subset of eight patients was identified (two males, six females) with locally advanced nonsmall cell lung cancer who underwent treatment planning SPECT/CT and PET/CT for definitive radiation therapy. The median patient age was 72.5 yr (60-79 yr) at the time of simulation. Three patients had T2N2M0 (stage IIIA) disease, and other patient stages included T3N0M0 (IIB), T3N2M0 (IIIB), T4N2M0 (IIIB), and T1N3M0 (IIIB). FLARE RT planning comparisons were conducted without any patient intervention.
2.B. SPECT/CT and PET/CT image acquisition, reconstruction, and registration
All patients underwent pretreatment [ 99m Tc]MAA SPECT/ CT scans during which they were immobilized in radiation treatment position. SPECT/CT images were acquired on a Precedence ™ (Philips Healthcare, Cleveland, OH) dual head gamma camera 16 slice CT scanner. A fixed intravenous injected dose was followed immediately by time-averaged SPECT acquisition (64 views, 20 s/view, 180 degree arc). Emission images were corrected for scatter, collimator-detector distance, and attenuation using a helical CT to promote semi-quantitative reproducibility. Reconstructions were performed with the Astonish ™ (Philips Healthcare, Cleveland, OH, USA) ordered subset expectation-maximization (OSEM) iterative algorithm which incorporates spatial resolution recovery. Images were reconstructed on 4.64 mm isotropic grids with a 10 mm cutoff Hanning filter.
All patients underwent pretreatment [ 18 F]FDG PET/CT scans. The majority of scans were completed with patients immobilized in treatment position, while the remaining were conducted as whole body treatment planning scans. PET/CT images were acquired on a Discovery STE ™ (GE Healthcare, Waukesha, WI, USA) scanner. Administration of a weightbased injection was followed by a standard 60 min uptake period (nominal). PET images were reconstructed with OSEM onto 5.47 9 5.47 9 3.27 mm 3 voxel grid with postreconstruction Gaussian filtration.
Treatment planning scans consisted of standard-of-care respiratory-correlated cine (4D) CT, in which targets were delineated on individual 4DCT phases and radiation dose was calculated on phase-averaged 4DCT. Rigid registration between the planning CT and SPECT/CT was performed in MIM 6.5 ™ (MIM Software Inc., Cleveland, OH, USA) using built-in mutual information methods. The resulting spatial transformations estimated from CT-to-CT registration were applied to the respective SPECT images, and the rigidly translated/rotated matrices were resampled using a cubic spline filter onto a common planning grid in MIM. The same process was applied to registration of the PET/CT to the planning CT. Preliminary evaluation of deformable registration techniques was performed but did not provide sufficiently improved registration accuracy to warrant their implementation for this study. We also did not utilize 4D PET for dose painting in this study due to significant dosimetric challenges 39 and limited applicability to locally advanced lung cancer patients whose bulky tumors exhibit lower motion amplitudes and aperiodic trajectories.
2.C. FLARE RT objectives
FLARE RT combines functional lung avoidance planning based on MAA SPECT/CT and tumor dose painting based on FDG PET/CT, in which both tumor dose and lung dose are simultaneously redistributed at the voxel scale. This dual dose-painting-by-numbers approach to generate clinically deliverable plans differs from previous efforts to combine functional tissue avoidance and tumor dose escalation. 36 Details of the functional tissue avoidance 40 and tumor dose painting 41, 42 techniques for compatibility with commercial treatment planning systems are reported in the literature. Specific to this study, lung planning substructures for avoidance were defined by automatic subthresholding into seven uptake bins/levels 40 equally spaced between the minimum and maximum normalized MAA SPECT uptake. Functional lung avoidance planning objectives for each perfusion level (PERF L i ) adhered to the equations listed in Table I , which redistributed 20 Gy mean lung dose according to the inverted relative mean uptake within each perfusion level. For example, a perfusion level with twice the mean normalized uptake relative to total lung mean uptake was limited to receive half of the total lung mean dose, or 10 Gy. This approach enabled the automatic selection of beam angles and arc segments by inverse planning optimization, which eliminated any variability due to forward planning manual beam selection.
The dose to highly perfused lung was evaluated within a region defined by a relative intensity threshold method, namely 70% of maximum lung MAA SPECT intensity. Other studies have defined percentiles of the functional lung intensity distribution, 26, 43, 44 which typically produced larger regions within the lung. For example, the reported 70th percentile 26 functional lung region consists of 30% of the total lung volume with highest function by definition, whereas the 70% threshold of maximum intensity used in this investigation creates smaller regions that vary as a percentage of the total lung volume. In our patient cohort, the highly perfused lung ROI volume measured less than 170 cc (median 75 cc), which comprised less than 5% of the total lung volume (median 2%). This threshold to define a highly perfused lung ROI was optimized by receiver-operator characteristic (ROC) analysis in our prior work. 34 It yielded the highest correlation between mean dose to highly perfused lung and incidence of National Cancer Institute Common Terminology for Adverse Events (CTCAE) v4 grade 2 or higher pneumonitis. 34 Reducing the mean dose to the highly perfused lung ROI below 15 Gy (13 Gy EQD2), in conjunction with maintaining the anatomic mean lung dose below 20 Gy, significantly reduced the risk of pulmonary toxicity. 34 These findings are currently being validated in the FLARE RT trial. The biological target volume (BTV) was defined by a union of manual contouring (GTV) and gradient search algorithm PET Edge ™ (MIM Software Inc. Cleveland, OH, USA). BTV planning substructures were defined by automatic subthresholding into seven uptake bins/levels 40 equally spaced between the minimum and maximum FDG standardize uptake value (SUV). BTV dose painting objectives for each FDG PET level (FDG L i ) adhered to the equations in Table I , which redistributed 14 Gy mean BTV concomitant boost dose (integrated above 60 Gy floor dose) according to the relative mean uptake within each FDG level. This prescription scheme was chosen to deliver similar integral doses as the RTOG 0617 experimental arm, but instead redistributed a uniform dose boost to preferentially target more FDG-avid regions. For example, an FDG PET level with twice the mean SUV relative to the BTV mean SUV was prescribed twice the mean BTV boost dose, or 28 Gy boost integrated with 60 Gy for a total mean dose of 88 Gy. The linear dose-painting-by-numbers distribution derived from discrete PET uptake levels 41 allows for peak doses substantially higher than 74 Gy. As a mirror to the differential avoidance of perfused lung, the tumor dose-painting-by-numbers objectives facilitated complete inverse planning optimization for dose escalation. For evaluation purposes of the high boost dose region, the SUV peak [45] [46] [47] volume was defined as a 1 cm diameter sphere centered on the voxel of maximum FDG PET uptake within the BTV.
The remaining planning objectives are listed in Table I for the PTV, ITV-subtracted lung, ITV-subtracted highly perfused lung, heart, spinal cord, esophagus, and brachial plexus. Table I defines acceptable (minor) and unacceptable (major) violations of clinical goals in accordance with the FLARE RT protocol (NCT02773238).
2.D. Treatment planning
FLARE RT plans were generated in RayStation 5.0 (RaySearch Laboratories AB, Stockholm, Sweden). Plans consisted of three radiation modality combinations: x-ray volumetric modulated arc therapy (VMAT), proton pencil beam scanning (PBS), and combined PBS for functional lung avoidance with VMAT for tumor dose painting (P + X). The P + X combination was selected under the assumption that proton PBS can deliver similar target dose while lowering normal tissue integral dose, including dose to regions of functional lung, while x-ray VMAT can achieve highly modulated boost doses required by tumor dose painting. Testing of the converse plan combination (VMAT functional lung avoidance and PBS tumor dose painting: X + P) resulted in inferior plans that failed to meet protocol planning goals (data not shown), due to higher normal tissue integral dose and spatial variation in target dose hotspots.
All plans were calculated on a 2 mm isotropic dose voxel grid. VMAT plans were optimized for delivery by a clinically commissioned 6 MV Infinity ™ linac with Agility ™ collimator (Elekta, Stockholm, Sweden). Independent two-arc optimization was conducted for a functional lung avoidance beam set, as well as the BTV boost beam set, which produced a total of four arcs per FLARE RT plan. Arc delivery times were restricted to 90-120 s delivery time per arc (nominal) and a leaf motion constraint of 0.7 cm/degree was enforced to be compliant with physical delivery limits. 48 VMAT dose was calculated by collapsed cone convolution. 49, 50 A reference VMAT photon plan was optimized for each patient without functional lung avoidance or FDG PET-guided dose escalation planning objectives for comparison.
PBS plans were optimized for delivery by a clinically commissioned IBA Proteus Plus ™ (Ion Beam Applications, Louvain-Neuve, Belgium) cyclotron-powered gantry system. Energy layer-dependent spot sizes ranged from 3 mm to 7 mm (nominal sigma). Automatic spot spacing based on spot size and automatic energy layer spacing based on pristine Bragg Peak width were utilized to construct spot spatial distributions. Robust optimization of spot position and intensity distributions include AE3% range uncertainty and AE3 mm setup uncertainty in all directions. [51] [52] [53] PBS FLARE RT plans were generated to robustly cover 100% of the CTV to prescription. PBS dose was calculated by pencil beam convolution 54 and reported with uniform relative biological effectiveness (RBE) scaling of 1.1. 55 Combination plans (P + X) utilized the same proton PBS beams for functional lung avoidance as with the proton FLARE RT plans, followed by the same photon VMAT arcs for tumor dose painting as with the VMAT FLARE RT plans.
2.E. Statistical analysis
FLARE RT plans were evaluated for compliance with the clinical trial protocol objectives of Table I . Planned dose parameters were compared for each patient between VMAT, PBS and P + X FLARE RT plans using the Friedman nonparametric multigroup paired test. P ≤ 0.01 was considered statistically significant following multiple sampling correction to suppress the false discovery rate. Linear regression between radiation dose to BTV and normalized FDG PET SUV at every voxel was conducted. Pearson linear correlation coefficients provided an estimate of fidelity to the linear redistribution of the BTV boost. Linear regression slopes were estimated for the magnitude of the dose redistribution BTV boost. Spearman rank correlation coefficients were estimated between radiation dose to lung and normalized SPECT uptake for groups of voxels binned by uptake. This approach mitigated statistical noise from low uptake regions getting low dose due to geometric constraints. FLARE RT plans did not penalize lung regions receiving lower dose than their planning objective, which allowed nonlinear dose redistribution for functional lung avoidance. All statistical calculations were performed in OriginPro 9.1 ™ (OriginLab Corporation, Northampton, MA, USA).
RESULTS
FLARE RT plans are shown for an example Stage III NSCLC patient in Fig. 1 . The FDG PET/CT fusion in Fig. 1(a) defines the nonuniform dose prescription within the biological target volume (red contour), with rainbow colorscale normalized to 0-10 SUV range, along with conventional coverage of 60 Gy to PTV (yellow contour). FLARE RT planned dose distributions that escalate dose based on relative FDG PET/CT SUV and avoid functional lung defined by relative MAA SPECT/CT uptake (hot metal colorscale) are shown for three delivery modalities: x-ray VMAT [ Fig. 1(c) ], proton PBS with robust optimization (3%/3 mm) [ Fig. 1(d) ], and combination PBS and VMAT [ Fig. 1(e) ]. Despite optimizing full VMAT arcs, only certain arc segments were heavily weighted to avoid perfused lung in the posterior aspect of the upper lobes. By contrast, the conventionally optimized VMAT plan [ Fig. 1(b) ] was highly conformal to the PTV, while increasing dose to highly perfused lung regions proximal to the target. Of note in this patient case was that FLARE PBS provided robust target coverage with higher skin dose, while FLARE VMAT target dose was highly conformal at the cost of increased lung dose.
FLARE RT dose-volume histograms (DVH) are shown for the same example Stage III NSCLC patient in Fig. 2, with comparison to DVH of the conventionally optimized clinical VMAT plan. FLARE VMAT reduced dose to highly perfused lung compared to the conventional VMAT plan, but irradiated the heart and spinal cord to higher doses. Similar PTV coverage and mean BTV dose was achieved across FLARE RT plan modalities, with higher dose to the FDG SUV peak volume using VMAT. For similar perfused lung mean doses, FLARE PBS provided reduced lung dose and cord dose compared to FLARE VMAT. The combination FLARE PBS and VMAT (P + X) provided a compromise between the lower normal tissue DVH curves of PBS with the higher target DVH curves of VMAT.
Linear dose redistribution for FDG PET-based dose painting within the BTV is shown for the same example Stage III NSCLC patient in Fig. 3 . Scatter plots of FLARE RT planned dose versus normalized FDG PET uptake at each BTV voxel show higher Pearson linear correlation using VMAT (R = 0.93) or P + X (R = 0.94) compared to PBS (R = 0.89). Note that VMAT and P + X plans achieved higher maximum doses of approximately 90 Gy, while the PBS plan achieved a lower maximum dose of around 83 Gy. As a mirror concept to tumor dose painting, dose redistribution for MAA SPECT-based avoidance within the lung is shown for the same example Stage III NSCLC patient in Fig. 4 . Binned MAA SPECT perfusion voxel uptake versus the mean planned dose shows more negative Spearman rank correlation using VMAT (R s = À0.73) compared to PBS or P + X (R S = À0.47). However, PBS and P + X produced lower integral lung dose for the same dose to highly perfused regions.
No unacceptable violations of objectives defined in Table I were encountered in the 24 FLARE RT plans. Minor (acceptable) violations were observed in PTV V 60 Gy and V 54 Gy , as well as ITV-subtracted lung V 5 Gy and V 10 Gy . Table II lists the patient sample medians and interquartile ranges for the planned dose parameters. Compared to conventionally optimized VMAT plans that did not incorporate MAA SPECT perfused lung avoidance or FDG PET-guided dose escalation, FLARE VMAT plans achieved a higher mean dose to BTV (73.7 Gy vs. 61.3 Gy) and higher mean dose to SUV peak (89.7 Gy vs. 60.8 Gy), while lowering the mean dose to highly perfused lung (7.3 Gy vs. 14.9 Gy). These dosimetric gains in FLARE VMAT came at the expense of higher mean heart dose (9.4 Gy vs. 5.8 Gy) and higher maximum cord dose (50.1 Gy vs. 44.6 Gy) compared to the reference clinical plans. When comparing FLARE RT planning modalities in Table II , FLARE VMAT achieved higher mean dose to SUV peak than FLARE PBS (89.7 Gy vs. 79.2 Gy), while FLARE PBS delivered lower mean dose to ITV-subtracted lung than FLARE VMAT (11.9 Gy vs. 15.6 Gy), as well as lower lung V 5 Gy (35% vs. 62%), lung V 10 Gy (29% vs. 46%) and maximum cord dose (15.6 Gy vs. 50.1 Gy). Patient sample distributions of mean dose to boost targets, lung, esophagus, and heart structures are visualized as box-whisker plots in Fig. 5 . Table III and Fig. 6 present the linear correlation between BTV dose and FDG PET SUV, the rank correlation between lung dose and MAA SPECT normalized uptake, and the linear regression slope for BTV boost dose redistribution. All modalities achieved similar lung dose |R Spearman | for functional tissue avoidance, while FLARE P + X showed a possible trend toward higher BTV R Pearson for tumor dose painting, with neither result achieving statistical significance (P > 0.07). Note in Fig. 6 that two patients had FLARE RT plans with weak correlation between lung dose and MAA SPECT normalized uptake, which was due to close spatial proximity of functional lung to the PTV and broader beam penumbra in the case of PBS plans. Voxelwise linear dose redistribution slope between BTV dose and FDG PET uptake was significantly higher in magnitude for FLARE P + X (0.36 Gy per %SUV max ) compared to FLARE VMAT (0.27 Gy per %SUV max ) or FLARE PBS alone (0.17 Gy per %SUV max ), with Friedman P = 0.002.
DISCUSSION
Safe radiation dose escalation strategies to improve local control, mitigate toxicity, and consequently prolong survival of patients with locally advanced nonsmall cell lung cancer are critically needed. We evaluated the treatment planning Scatter plots of FLARE RT planned dose versus normalized MAA SPECT binned uptake within the lung for VMAT (red), PBS (green), and combination PBS + VMAT (P + X, blue) for an example Stage III NSCLC patient. The MAA SPECT perfusion voxel uptake distribution was partitioned into 100 bins and the mean planned dose within each bin is plotted for clarity. Dose redistribution within the lung was evaluated by Spearman rank correlation coefficient. Note that while VMAT dose redistribution is more negatively rank correlated with normalized uptake, PBS and P + X dose redistribution achieves lower integral lung dose. [Color figure can be viewed at wileyonlinelibrary.com] feasibility of one such strategy, Functional Lung Avoidance and Response-adaptive Escalation (FLARE) Radiation Therapy (RT), for testing in a phase II clinical trial (NCT02773238). FLARE RT plans in this sample of patients could achieve between 70 and 74 Gy mean dose to the FDG PET-defined biological target volume (BTV) without incurring unacceptable planning violation in normal tissue constraints. The vast majority of plans (22 of 24) limited the mean dose to highly perfused lung under 10 Gy while all plans maintained the total mean lung dose under 20 Gy. Dosimetric tradeoffs in heart and spinal cord doses were noted between conventionally optimized VMAT plans and FLARE VMAT plans. Further tradeoffs were noted between the FLARE RT planning modalities, as VMAT could generally redistribute the BTV dose across a higher dynamic range (maximum doses exceeding 90 Gy), while proton pencil beam scanning (PBS) reduced lung integral dose and maximum cord dose. The combination of PBS for functional lung avoidance with VMAT for FDG PET-guided tumor dose escalation offered a unique opportunity to mitigate their respective weaknesses while leveraging their respective strengths. Specifically, FLARE RT plans covered the PTV with a uniform floor dose of 60 Gy while minimizing integral dose to lung using PBS, and then integrated a nonuniform dose distribution within the BTV using VMAT to achieve high dose conformity and reduce sensitivity to range/setup/motion uncertainties. Multimodality radiation therapy may provide synergy when designing personalized treatment regimens.
Other studies have reported on the technical feasibility of incorporating avoidance of functional lung irradiation into treatment planning 26, 36, 43, 44, [56] [57] [58] [59] or tumor dose painting based on FDG PET in lung cancer. 32, 36 Functional tissue avoidance studies observed that the degree of functional lung irradiation was highly dependent on the geometric concentricity of perfused or ventilated lung regions around the target volume. Functional lung regions that were concave in shape around the target could not be avoided without compromising target dose conformity. These functional lung avoidance planning studies collectively reported 1-4 Gy mean dose reductions to functional lung, 26, 43, 44, 59 whose definition varied by imaging modality (lung perfusion vs. ventilation, SPECT/ PET/4DCT/MRI) and by segmentation method (image intensity distribution percentile, image intensity threshold relative to maximum intensity). Similarly, FLARE RT plans reduced dose conformity to the PTV in exchange for increased conformal avoidance of functional lung without losing target dose coverage. However, a key distinction in our investigation was that the definition of highly perfused lung produced smaller volumes whose mean doses exhibited high variability between patients and plans, leading to dose reductions of more than 7 Gy between FLARE VMAT and conventional VMAT. Evaluation of doses to perfused lung using a published 70th percentile definition 26 led to planned dose reductions in our patient cohort of 2 Gy (data not shown), which is in keeping with other studies. Beyond perfused lung dose, FLARE RT plan dosimetry tended to be constrained by cord dose in the case of VMAT technique due to inversely optimized arc angles or skin dose in the case of PBS technique due to limited beam number.
Tumor dose painting studies based on FDG PET primarily focused on planned dose equivalence with prescribed dose at every voxel, and used quality indices (e.g., Q rms , V Q0.95-1.05 ) to estimate the relative error between plan and prescription at the voxel scale. [60] [61] [62] By contrast, FLARE RT plans were constructed to redistribute dose in the BTV about a mean of 74 Gy with two priorities: (a) maintaining 60 Gy PTV coverage, and (b) linearly escalating BTV dose at every voxel according to its relative FDG avidity. Thus, metrics for FLARE plan quality were not bound to an empiric voxel prescription but rather to the mean BTV dose and linearity of dose redistribution. This design allowed for scaling of the dynamic range in BTV voxel doses in order to respect patient-specific normal tissue dose constraints, all while maintaining the relative shape of the BTV dose distribution to preferentially irradiate FDG-avid regions at higher risk of local failure. It will also facilitate comparison between the RTOG 0617 historical control and the FLARE RT clinical trial that spatially redistributes similar integral dose.
The investigation has notable limitations. First, we report on a small patient sample size. However, four independent plans were generated for each patient (eight conventional VMAT plans, 24 FLARE RT plans total) to power multigroup paired Friedman testing that identified trends and tradeoffs in planning, which are likely to be generalizable to future FLARE RT patient plans. Second, FLARE RT planning in this feasibility study was based on pretreatment SPECT/CT and PET/CT without consideration for midtreatment changes in perfused lung or tumor metabolic status. Independent data from our institution suggest that midtreatment perfused lung spatial distributions on MAA SPECT are highly correlated with pretreatment distributions (data not shown), which will be reported in the context of a perfused lung dose-response investigation. This implies that functional lung avoidance based on pretreatment imaging defines spatially stable regions over the course of therapy. Due to strong evidence on the prognostic value of midtreatment TABLE III. Correlation between BTV and FDG PET (BTV R Pearson ), correlation between lung dose and MAA SPECT normalized uptake (Lung |R Spearman |), and linear regression slope of BTV dose redistribution. The patient sample median and interquartile ranges (IQR) are listed for each parameter, and pairwise differences between the three treatment delivery modalities (VMAT, PBS, P + X) were evaluated by nonparametric Friedman test. P ≤ 0.01 considered statistically significant following multiple sampling correction to suppress false discoveries. FDG PET/CT changes, 13, 63 the FLARE RT clinical trial will assess response and adapt plans accordingly. In this precursor treatment planning study, all patients were planned to include tumor dose escalation at baseline, which provided conservative bounds on feasibility as it is more technically challenging to dose-escalate all patients prior to any tumor metabolic response or tumor volume regression during therapy. Our results indicate that adapting FLARE RT for dose escalation partway into treatment will remain technically feasible. Lastly, the investigation did not consider additional heart dose limits beyond those conventionally reported. In light of recent reports that heart dose was associated with worse overall survival, 1,64 one could explicitly place more restrictive planning constraints to reduce risk of cardiac toxicity. Under conventional dose limiting objectives, FLARE RT plans achieved mean heart doses between 5 and 10 Gy for most patients while keeping mean heart dose in all patients below 15 Gy. The implementation of functional lung avoidance in our patient sample did not excessively increase the planned heart dose.
Our FLARE RT strategy generated clinically deliverable plans that simultaneously combined functional lung avoidance with tumor dose escalation guided by MAA SPECT/CT and FDG PET/CT, respectively, for testing in locally advanced NSCLC patients within a phase II clinical trial (NCT02773238). We applied a dual dose-painting-by-numbers approach that accounted for spatial heterogeneity at the image voxel scale in tumor metabolism and lung perfusion within a commercial treatment planning system. Under the FLARE RT trial, daily image guidance with CBCT and weekly 4D-CBCT or QA 4DCT scans will help ensure the accuracy of treatment delivery and consistency of tumor motion. Both photon VMAT and proton PBS treatment modalities produced compliant planned dose distributions, which we will implement in the FLARE RT trial by leveraging institutional experience on robust proton PBS plan optimization 52, 53 and volumetric rescanning 65 to mitigate interplay effects during delivery. This may include future application of the P + X multimodality planning technique as part of a logistical workflow for treatment delivery across sites of practice.
Interim analyses in the forthcoming years on FLARE RT plan dosimetry, toxicity, and local tumor control will shed further light on the efficacy of this precision oncology strategy. Clinical outcomes of the FLARE RT trial will be compared to the RTOG 0617 historical control. 1 The dosimetric and imaging drivers of these outcomes following FLARE RT may identify complementarity with ongoing trials testing different functional lung avoidance strategies 27, 66 , as well as those testing different dose escalation strategies 17, 67 in locally advanced NSCLC. Combined approaches may lead to optimization of future precision radiation therapy trial design.
CONCLUSION
Our study characterized the clinical plan dosimetry of FLARE RT using photon VMAT or proton PBS delivery technique. A combination of PBS for functional lung avoidance and VMAT for FDG PET-guided dose escalation provided synergy in the optimization of target and normal tissue clinical goals. The presented technical platform will allow for testing of FLARE RT safety and efficacy within a precision radiation oncology trial.
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